Unlocking the Next
Chapter of Kidney Care
Meet the Expert Series: Video On Demand-Prof. Merlin Thomas
CV Mortality and HHF and CV Death secondary endpoint did not reach statistical Significance in EMPA Kidney. How should we view this result in relation to the Other Empagliflozin trials?
Related Videos
1:10
EK22||What for you are important Renal Outcomes to remember in EMPA REG, and EMPA KIDNEY that demonstrates the benefit of SGLT2i in CKD?
6:42
EK22||Hypertensive, Newly Diagnosed with CKD not on SGLT2i, what is your usual approach managing this patient based on your Practice
1:31
EK22||In a Diabetic patient newly diagnosed with CKD not on SGLT2i, how is your practice initiating SGLT2i if patient is also not on RAASI?
08:35
EK22||How can we improve Shared Care Approaches for Specialist and Primary Care Physicians in managing patients with CKD and Cardio Renal and Metabolic conditions for better patient care?
Document ID: SC-ASK-00684